In this issue
Issue 128 • March 2023
In the last few years, there have been growing calls to onshore the manufacturing of certain pharma products, including active pharmaceutical ingredients (API), to ensure a smooth supply and to minimise shortages in the European Union (EU). In this month’s cover story, we explore what this ‘reshoring’ might look like amidst rising inflation and how to get these plans right in the EU.
Also in this month’s issue, we take a look at the innovative type 1 diabetes therapy by Provention Bio called Tzield. More than a century after an individual with type 1 diabetes was treated with insulin for the first time, the FDA approved Tzield, the first and only treatment to delay the onset of type 1 diabetes. But experts tell us that wider screening programs are needed to address existing inequities in this space and to ensure all eligible patients get access to this treatment.
Don’t miss an in-depth feature looking at the latest trends in decentralised clinical trials, and the story behind the development of Alzheimer’s disease vaccines.
All this, and the latest pharma industry news, comment, and analysis from GlobalData.
Manasi Vaidya, editor